HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer
- PMID: 40849586
- DOI: 10.1038/s41388-025-03548-0
HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer
Abstract
(Yes-associated protein 1) YAP1 is frequently activated in human prostate cancers (PCa), but the underlying regulatory mechanism remains elusive. Here, we identified a novel scaffold protein HOMER3 in PCa, that can promote YAP1 activity by disrupting LATS-YAP1 phosphorylation. Mechanistically, HOMER3 overexpression in PCa facilitates the SRC kinase to phosphorylate YAP1 accompanied by counteracting LATS1-mediated YAP1 inhibition, thereby maintaining high YAP1 nuclear localization and transcriptional activity. Accordingly, HOMER3 gain-of-function in PCa cells phenocopies the effect of YAP1 activation, including cell hyperproliferation in vitro and rapid tumor growth in vivo. Additionally, transcriptome analysis revealed that CD274 is consistently upregulated in HOMER3 overexpressing PCa cells and patients, which eventually contributed to an immunosuppressive phenotype. More importantly, blocking SRC kinase-mediated YAP1 activation improved the immunotherapy-insensitive phenotypes in PCa caused by HOMER3 overexpression. Taken together, our findings define a novel kinase-substrate interactive platform for HOMER3 to orchestrate YAP1 activity in PCa. Targeting SRC-YAP1 oncogenic axis provides new insights into the therapeutic potential for PCa patients carried HOMER3 overexpression.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics: Written informed consent was obtained from all patients and the study was approved by the Ethics Committee of the Seventh Affiliated Hospital, Sun Yat-sen University (KY-2024-069-02). Animal experiments were performed according to the Health Guide for the Care and Use of Laboratory Animals approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University (SYSU-IACUC-2024-002513). All methods were performed in accordance with relevant guidelines and regulations.
Similar articles
-
USP14 inhibition by degrasyn induces YAP1 degradation and suppresses the progression of radioresistant esophageal cancer.Neoplasia. 2025 Feb;60:101101. doi: 10.1016/j.neo.2024.101101. Epub 2024 Dec 14. Neoplasia. 2025. PMID: 39675091 Free PMC article.
-
Hippo pathway-mediated YAP1/TAZ inhibition is essential for proper pancreatic endocrine specification and differentiation.Elife. 2024 Jul 25;13:e84532. doi: 10.7554/eLife.84532. Elife. 2024. PMID: 39051998 Free PMC article.
-
FV-429 suppresses cancer cell migration and invasion by EMT via the Hippo/YAP1 pathway in pancreatic cancer cells.Anticancer Drugs. 2025 Aug 1;36(7):527-538. doi: 10.1097/CAD.0000000000001718. Epub 2025 Mar 12. Anticancer Drugs. 2025. PMID: 40071582
-
The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives.Cancer Lett. 2024 Nov 1;604:217244. doi: 10.1016/j.canlet.2024.217244. Epub 2024 Sep 10. Cancer Lett. 2024. PMID: 39260668 Free PMC article. Review.
-
Epigenetic alterations in prostate cancer: the role of chromatin remodeling.Epigenomics. 2025 Jul 22:1-25. doi: 10.1080/17501911.2025.2535938. Online ahead of print. Epigenomics. 2025. PMID: 40694614 Review.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous